Ginkgo Biloba: A Critical Review of the Cognitive and Circulatory Research

This article is for educational and research purposes only and does not constitute medical advice. Consult a qualified healthcare practitioner before use, especially if taking prescription medications.

Ginkgo biloba is one of the most studied botanical supplements in the world, and also one of the most misrepresented. The research literature on Ginkgo spans more than four decades, encompasses thousands of published studies, and has produced a genuinely mixed picture — strong signals in specific populations, null or negative results in others, and ongoing debate about which product formulations and patient groups are most likely to benefit. This article reviews the evidence honestly: what the research supports, where it falls short, and what practical conclusions can reasonably be drawn.

Background: The Living Fossil

Ginkgo biloba is the sole surviving species of the division Ginkgophyta, a plant lineage that predates the dinosaurs by roughly 50 million years. Individual trees can live for over a thousand years, and the species has remained morphologically unchanged for approximately 200 million years — earning it the designation "living fossil." The leaves and seeds have been used in Chinese medicine for centuries, primarily for respiratory and circulatory conditions.

Modern pharmaceutical interest began in Germany in the 1960s, where researchers at Dr. Willmar Schwabe Pharmaceuticals developed a concentrated, standardised leaf extract that became the basis for the most widely studied preparation: EGb 761. This extract remains the benchmark formulation in clinical research and is meaningfully different from raw ginkgo leaf powder or non-standardised products.

Active Compounds and Mechanisms

Flavonoid Glycosides

Approximately 24% of EGb 761 by weight consists of flavonoid glycosides, primarily kaempferol, quercetin, and isorhamnetin glycosides. These compounds are responsible for much of Ginkgo's antioxidant activity, scavenging reactive oxygen species (ROS) and reducing oxidative stress in neural and vascular tissues. Quercetin, in particular, is a well-characterised anti-inflammatory compound that inhibits several pro-inflammatory pathways in cell culture and animal models.

Terpenoids: Ginkgolides and Bilobalide

The terpenoid fraction (approximately 6% of EGb 761) comprises the pharmacologically distinctive compounds unique to Ginkgo:

• Ginkgolides A, B, C, J, and M: Diterpene lactones that act as potent antagonists of platelet-activating factor (PAF). PAF is a phospholipid mediator involved in platelet aggregation, inflammation, and bronchoconstriction. Ginkgolide B is the most potent PAF antagonist in this group and is the basis for much of Ginkgo's cardiovascular and blood-flow research.
• Bilobalide: A sesquiterpene lactone with neuroprotective properties in animal models. Research suggests bilobalide may protect neurons against ischaemic injury, reduce apoptotic signalling under oxidative stress, and modulate GABA-A receptor activity.

Key Mechanisms

The mechanisms most consistently supported by research include:

1. PAF inhibition: Reduces platelet aggregation and supports microcirculatory flow, particularly in peripheral and cerebral vasculature.
2. Nitric oxide modulation: Ginkgo flavonoids support endothelial NO production, promoting vasodilation and improved blood flow.
3. Antioxidant activity: Reduces oxidative damage in neuronal and vascular tissue, relevant to both ageing-related cognitive decline and vascular endothelial health.
4. Mitochondrial support: Animal and cell culture studies suggest Ginkgo compounds improve mitochondrial membrane potential and reduce mitochondrial ROS production.
5. Neurotransmitter modulation: Research indicates Ginkgo influences serotonin, dopamine, and acetylcholine receptor activity, though the clinical significance of these effects in humans remains under investigation.

For further context on how inflammation intersects with cognitive decline, inflammation and cognitive decline provides a useful reference on biomarker patterns associated with neuroinflammatory processes.

The Cognitive Evidence: Parsing a Complex Literature

Where Ginkgo Shows the Clearest Benefit

The most consistent positive signals in the Ginkgo cognitive literature come from two specific populations:

Mild cognitive impairment (MCI) and early dementia: Multiple European trials using EGb 761 at 240 mg/day found statistically significant improvements in cognitive test scores (particularly on neuropsychological batteries assessing memory, attention, and executive function) and reduced caregiver-rated functional decline compared to placebo. A 2016 meta-analysis published in Ageing Research Reviews pooled data from six randomised controlled trials using EGb 761 240 mg/day and found consistent benefit in patients with mild-to-moderate Alzheimer's disease and vascular dementia on both cognitive and functional outcome measures.

Vascular dementia: Given Ginkgo's mechanisms of action (PAF inhibition, NO support, microcirculation), the plausible biological rationale for benefit in vascular dementia is stronger than in amyloid-driven Alzheimer's pathology. Clinical trial results in this subgroup have been more consistently positive than in Alzheimer's disease specifically.

For context on other botanicals with evidence in cognitive ageing, Bacopa memory research covers a well-studied nootropic with a distinct cholinergic-focused mechanism and a different evidence profile.

Where the Evidence Is Mixed or Negative: Healthy Adults

The picture is substantially less clear when it comes to healthy adults with no evidence of cognitive impairment. Several well-designed trials in this population have found no significant benefit from Ginkgo supplementation on standard cognitive measures, including:

• Memory recall and recognition
• Processing speed
• Working memory capacity
• Executive function

A 2002 JAMA study by Solomon et al. (n=203, healthy adults over 60) found no benefit from Ginkgo extract on memory or related cognitive tasks over a six-week period. A 2008 study by Elsabagh et al. in healthy young adults (mean age approximately 22 years) also found no significant cognitive enhancement.

The honest interpretation is that Ginkgo does not appear to function as a general cognitive enhancer in neurologically healthy individuals — at least not at doses and durations studied to date.

The GINKGO Evaluation of Memory (GEM) Trial

The GEM trial is the largest and most methodologically rigorous Ginkgo study conducted to date, and its results significantly tempered earlier optimism about the supplement's potential for dementia prevention.

Published in JAMA in 2008, the GEM trial enrolled 3,069 community-dwelling adults aged 75 years and older (or 72 and older with a family history of dementia) without dementia at baseline. Participants were randomised to Ginkgo biloba extract (EGb 761 equivalent, 120 mg twice daily, totalling 240 mg/day) or placebo and followed for a median of 6.1 years — making it one of the longest botanical supplement RCTs ever conducted.

The primary finding: Ginkgo biloba did not reduce the incidence of Alzheimer's dementia or overall dementia compared to placebo (hazard ratio 1.12, 95% CI 0.94-1.33). Secondary analyses also found no significant effect on cognitive decline rates, cardiovascular events, or functional status.

The GEM trial is an important corrective to overclaiming. It does not rule out potential benefit in already-diagnosed mild cognitive impairment (the trial studied prevention in at-risk but cognitively normal adults), but it effectively closes the case on Ginkgo as a dementia-prevention strategy for the general elderly population.

The GEM results stand in contrast to the positive findings in already-impaired populations, which raises a plausible hypothesis: Ginkgo may support symptomatic management in existing cognitive impairment without preventing the underlying pathological progression.

Neuroimaging and Mechanistic Studies

Functional neuroimaging studies (fMRI, PET) in small samples have shown that Ginkgo administration is associated with altered regional cerebral blood flow patterns in areas associated with memory and attention processing. While intriguing as mechanistic evidence, these studies have not consistently translated into detectable differences on standard cognitive performance measures in healthy adults.

Tinnitus and Vertigo

Tinnitus

Tinnitus — the perception of sound in the absence of an external auditory stimulus — has been a long-standing indication for Ginkgo in European prescribing practice, based on the rationale that inner ear microcirculation deficits may contribute to some forms of tinnitus.

The trial evidence is genuinely mixed. Some studies using EGb 761 at standard doses report subjective improvement in tinnitus severity and annoyance scores compared to placebo; others, including a well-conducted UK trial (Drew and Davies, 2001, BMJ, n=978), found no significant benefit. The most recent Cochrane review on Ginkgo for tinnitus (updated 2022) concluded that there is no reliable evidence that Ginkgo is effective for tinnitus as a primary complaint, though it noted that patients with tinnitus secondary to cognitive impairment or vascular dementia may benefit as part of broader treatment.

Vertigo and Balance

The evidence for Ginkgo in vestibular dysfunction and vertigo is slightly more positive than for tinnitus, with several European trials reporting reduced vertigo frequency and improved balance test scores with EGb 761. The biological rationale (improved inner ear microcirculation, reduced PAF-mediated vestibular inflammation) is plausible, but the evidence base remains modest in size and quality.

Circulation and Peripheral Vascular Effects

Beyond the CNS, Ginkgo has a reasonable evidence base for peripheral circulatory effects:

Intermittent claudication: Multiple trials have found that Ginkgo (EGb 761, 120-240 mg/day) significantly increases pain-free walking distance in patients with peripheral arterial disease (PAD) and intermittent claudication compared to placebo. A Cochrane review (2013) concluded the effect is modest but statistically significant, with a mean improvement of approximately 35 metres in pain-free walking distance — clinically meaningful but smaller than exercise rehabilitation.

Raynaud's phenomenon: Small trials suggest Ginkgo may reduce the frequency of vasospastic attacks in Raynaud's disease, consistent with its PAF inhibition and vasodilatory mechanisms.

EGb 761 vs Raw or Non-Standardised Products

This distinction matters considerably and is not always communicated clearly to consumers.

EGb 761 is a highly processed, standardised extract manufactured to contain 24% flavonoid glycosides and 6% terpene lactones, with ginkgolic acids (potentially allergenic and toxic compounds found in raw Ginkgo) reduced to a maximum of 5 parts per million. The extraction and standardisation process is proprietary and not replicable by generic manufacturers without significant process validation.

Raw ginkgo leaf powder has a variable and generally much lower concentration of active compounds, unpredictable ginkgolic acid content, and no controlled clinical trial evidence base behind it. The majority of positive trial evidence for Ginkgo — including all the major dementia and cognitive trials — used EGb 761 or its close generic equivalents standardised to the same specification.

For practical purposes, consumers should look for products stating "standardised to 24% flavonoid glycosides and 6% terpene lactones" and manufactured to pharmaceutical GMP standards. Price is often a reasonable proxy for quality in this category.

Similarly, Lion's Mane cognitive research illustrates how standardisation matters for functional mushroom extracts — the same principle of extract quality versus raw powder applies across botanical and fungal nootropics.

Drug Interactions and Safety

Anticoagulants and Antiplatelet Agents — Priority Concern

Ginkgo's PAF inhibition and flavonoid-mediated effects on platelet aggregation create a genuine and well-documented interaction risk with anticoagulant and antiplatelet medications:

• Warfarin: Case reports and pharmacokinetic studies document increased bleeding risk when Ginkgo is co-administered with warfarin. The interaction appears to involve both pharmacodynamic (additive antiplatelet effects) and pharmacokinetic (CYP enzyme modulation) mechanisms.
• Aspirin and clopidogrel: Additive antiplatelet effects increase bleeding risk, particularly gastrointestinal and intracranial bleeding.
• Heparin and low-molecular-weight heparins: Theoretical additive risk; avoid co-administration without medical supervision.
• NSAIDs: Increased risk of bleeding with chronic combined use.

This interaction profile is not theoretical — there are published case reports of spontaneous intracranial haemorrhage in individuals taking Ginkgo alongside anticoagulants. Anyone on blood-thinning medication must not add Ginkgo without explicit medical clearance.

Seizure Threshold

Ginkgolides may lower the seizure threshold in susceptible individuals. Ginkgo is contraindicated in patients with epilepsy or those on antiepileptic medications without specialist review.

Drug Metabolism Interactions

Like many botanical extracts, Ginkgo modulates cytochrome P450 enzymes, particularly CYP2C9, CYP3A4, and CYP1A2. This creates potential interactions with a wide range of drugs metabolised by these enzymes, including some antidepressants, statins, and antifungal agents.

Pregnancy

Ginkgo is not recommended during pregnancy. Ginkgolide B has PAF-antagonist activity that could theoretically affect placental function, and there is no safety data from controlled human pregnancy studies.

Common Side Effects

At standard doses, Ginkgo is generally well-tolerated in healthy adults. Reported side effects include headache (particularly early in supplementation), gastrointestinal upset, dizziness, and allergic skin reactions. Rare but serious adverse events (primarily haemorrhagic) have been reported, predominantly in individuals with co-existing bleeding risk factors.

Practical Guidance

For individuals and practitioners considering Ginkgo:

1. Use standardised EGb 761 or equivalent (24% flavonoid glycosides, 6% terpene lactones, <5 ppm ginkgolic acids). Raw leaf powder is not supported by the trial evidence.
2. Standard research dose: 120-240 mg per day, typically split into two doses with meals. Most positive cognitive trials used 240 mg/day.
3. Allow adequate trial duration: Cognitive effects in impaired populations required 12-24 weeks to reach significance in most trials. Short trials of 4-6 weeks are unlikely to be informative.
4. Realistic expectations for healthy adults: The evidence does not support Ginkgo as a cognitive enhancer for neurologically healthy individuals. If cognitive enhancement in a healthy adult is the goal, nootropic peptide research Australia covers a different class of research compounds with distinct mechanisms being studied for this purpose.
5. Bleeding risk is real: Disclose Ginkgo use to any prescribing physician, particularly before surgery or if taking any anticoagulant, antiplatelet, or anti-inflammatory medication.
6. Strongest evidence: Mild cognitive impairment, vascular dementia (symptomatic management), peripheral arterial disease (claudication), possibly tinnitus secondary to vascular causes.
7. Weakest or absent evidence: Dementia prevention in healthy elderly, general memory enhancement in healthy adults, primary tinnitus without vascular aetiology.

Conclusion

Ginkgo biloba is a pharmacologically active botanical with genuine mechanisms and a large evidence base — but that evidence base tells a more selective story than supplement marketing typically conveys. The PAF inhibition, antioxidant, and microcirculatory mechanisms are well-characterised. The clinical benefit in mild cognitive impairment and vascular dementia is reasonably well-supported. The aspiration of dementia prevention in healthy elderly individuals was directly tested in the GEM trial and not confirmed.

Applying the research carefully — using the right preparation (EGb 761-standardised), at the right dose (240 mg/day), in the right population (those with existing mild cognitive impairment or vascular dementia), and with appropriate attention to drug interactions — gives Ginkgo a legitimate if circumscribed role in evidence-informed natural health practice. Treating it as a universal cognitive enhancer or prevention strategy goes beyond what the research currently supports.

---

This review reflects the published literature as of 2026. The evidence base for Ginkgo biloba continues to evolve. Individual responses to botanical supplements vary; consult a qualified healthcare practitioner for personalised guidance.